文献
J-GLOBAL ID:202002269288247120
整理番号:20A2530459
三環スルホンアミドによる蛋白質ホスファターゼ2A(PP2A)の直接活性化は,細胞および動物モデルにおけるアルツハイマー病の病因を改善する【JST・京大機械翻訳】
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models
著者 (16件):
Wei Hui
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Zhang Hui-liang
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Wang Xiao-chuan
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Xie Jia-zhao
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
An Dan-dan
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Wan Lu
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Wang Jian-zhi
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Zeng Yi
(Clinical Laboratory, The Central Hospital of Wuhan, Wuhan, China)
,
Shu Xi-ji
(Department of Pathology and Pathophysiology, School of Medicine, Jianghan University, Wuhan, China)
,
Westermarck Jukka
(Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland)
,
Westermarck Jukka
(Institute of Biomedicine, University of Turku, Turku, Finland)
,
Lu You-ming
(The Institute for Brain Research, Collaborative Innovation Center for Brain Science, Huazhong University of Science and Technology, Wuhan, China)
,
Ohlmeyer Michael
(Icahn School of Medicine at Mount Sinai, New York, NY, USA)
,
Ohlmeyer Michael
(Atux Iskay LLC, Plainsboro, NJ, USA)
,
Liu Rong
(Department of Pathophysiology, Key Laboratory of Ministry of Education for Neurological Disorders, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China)
,
Liu Rong
(The Institute for Brain Research, Collaborative Innovation Center for Brain Science, Huazhong University of Science and Technology, Wuhan, China)
資料名:
Neurotherapeutics
(Neurotherapeutics)
巻:
17
号:
3
ページ:
1087-1103
発行年:
2020年
JST資料番号:
W4806A
ISSN:
1933-7213
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
ドイツ (DEU)
言語:
英語 (EN)